Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6

Clinical & Experimental Metastasis

Volumn 13, Issue 2, 1995, Pages 116-122

  Marutsuka, Kousuke ^a   Hasui, Yoshihiro ^a   Asada, Yujiro ^a   Naito, Seiji ^b   Osada, Yukio ^a   Sumiyoshi, Akinobu ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

human renal cell carcinoma; metastasis; PAI 2; suramin; UPA

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 2; SURAMIN; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY CARCINOMA; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN;

ANIMAL; CARCINOMA, RENAL CELL; CELL DIVISION; KIDNEY NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; SURAMIN; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0028898080     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/BF00133616     Document Type: Article

References (27)

1. Suramin: A novel antineoplastic agent with multiple potential mechanisms of action
2. Recent research on the biological activity of suramin
3. Plasminogen activators, tissue degradation, and cancer
4. The relevance of plasminogen activators to neoplastic growth
5. Comparative study of plasminogen activator antigens in colonic carcinomas and adenomas
6. Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder
7. Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells
8. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer
9. In vivo selection of human renal cell carcinoma cells with high metastatic potential in nude mice
10. Disruption of cellular energy balance by suramin in intact human prostatic carcinoma, a likely antiproliferative mechanism
11. Disruption of mitochondrial function by suramin measured by rhodamine 123 retention and oxygen consumption in intact DU 145 prostate carcinoma cells
12. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
13. Effects of suramin on in vitro growth of fresh human tumors
14. Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction
15. Suramin interference with transforming growth factor-β inhibition of human renal cell carcinoma in culture
16. Inhibition of lung and liver tumor colonies in mice pretreated with suramin
17. Quantification of suramin by reverse-phase ion-pairing highperformance liquid chromatography
18. Experimental animal model for mucopolysaccharidosis: suramin-induced glycosamino glycan and sphingolipid accumulation in the rat
19. Effects of suramin on complement, blood clotting, fibrinolysis and kinin production
20. Suramin: a potent inhibitor of melanoma heparanase and invasion
21. Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins
22. Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin
23. Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin
24. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator
25. A pilot study of suramin in the treatment of metastatic renal cell carcinoma
26. Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression